Sino Biopharmaceutical Limited

Sino Biopharmaceutical Limited's next confirmed earnings release is scheduled for April 1, 2027.

As of December 31, 2021, Sino Biopharmaceutical Limited has 18.84B shares outstanding.

As of December 31, 2021, Sino Biopharmaceutical Limited maintains a current ratio of 1.53, meaning it holds 1.5x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2021.

Over the twelve months ended December 31, 2021, Sino Biopharmaceutical Limited recorded 176.86M in income tax expense.

As of December 31, 2021, Sino Biopharmaceutical Limited holds 2.27B in cash and equivalents against 1.74B in total debt, resulting in a net debt position of 167.19M. Total book value stands at 4.35B, with working capital of 1.17B providing operational flexibility.

Sino Biopharmaceutical Limited's most recent stock split took place on July 20, 2020 with a 2:3 split ratio.